Predicting and Preventing Positive Surgical Margins and Local Failures in Breast-Conserving Surgery
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To the Editor
Standard treatment of early-stage breast cancer includes breast-conserving surgery (BCS).1 Despite advances with radiation and adjuvant empirical cytotoxic and targeted systemic treatment, tumor-free surgical margins continue to play an important role in preventing local recurrence, and thus it is considered essential in designing treatment strategies.2,3
Prediction of surgical margins in both first surgical resection and reexcision is a helpful tool to prevent positive margins and to select the appropriate extent of surgery. Therefore, the report by Kurniawan and colleagues for the potential prediction of surgical margins will attract the attention of surgeons.4 On the basis of a population-based breast-screening program in Melbourne, Australia, these authors evaluated clinicopathologic data on 2160 women diagnosed with ductal carcinoma-in-situ or invasive cancer and treated with BCS.
Kurniawan et al. conclude that after BCS, patients with mammographic microcalcifications, ...
- Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44. CrossRef
- Roukos DH, Kappas AM, Agnantis NJ. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol. 2003;10:718–21. CrossRef
- Fatouros M, Roukos DH, Arampatzis I, et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther. 2005;5:737–45. CrossRef
- Kurniawan ED, Wong MH, Windle I. Predictors of surgical margin status in breast-conserving surgery within a breast screening program. Ann Surg Oncol. 2008;15:2542–9. CrossRef
- Roukos DH. Linking contralateral breast cancer with genetics. Radiother Oncol. 2008;86:139–41. CrossRef
- Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.
- Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–9. CrossRef
- Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. 2008;15:21–33. CrossRef
- Roukos DH, Murray S, Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther. 2007;6:308–12. CrossRef
- Roukos DH, Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol. 2007;4:578–90. CrossRef
- Roukos DH. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007;357:1555–6. CrossRef
- Pierce LJ, Levin AM, Rebbeck TR, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437–43. CrossRef
- Roukos DH, Lykoudis E, Liakakos T. Genomics and challenges toward personalized breast cancer local control. J Clin Oncol. 2008;26:4360–1. CrossRef
- Roukos DH, Kappas AM, Tsianos E. Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol. 2002;9:607–9.
- Roukos DH, Agnanti NJ, Paraskevaidis E, et al. Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol. 2002;9:941–3.
- Agnantis NJ, Paraskevaidis E, Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol. 2004;11:1030–4. CrossRef
- Chung DC, Yoon SS, Lauwers GY, et al. Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer. N Engl J Med. 2007;357:283–91. CrossRef
- Ziogas D, Baltogiannis G, Fatouros M, et al. Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg. 2008;247:714–5. CrossRef
- Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol. 2002;9:828–30. CrossRef
- Roukos DH. Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol. 2004;11:127–9. CrossRef
- Briasoulis E, Fatouros M, Roukos DH. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol. 2007;14:2691–5. CrossRef
- Roukos DH. Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol. 2002;9:220–1. CrossRef
- Briasoulis E, Liakakos T, Dova L, et al. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther. 2006;6:931–9. CrossRef
- Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery. 1998;123:573–8. CrossRef
- Roukos DH. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn. 2008;8:587–97. CrossRef
- Roukos DH. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn. 2008;8:29–39. CrossRef
- Liakakos T, Roukos DH. More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol. 2008;15:956–60. CrossRef
- Roukos DH. Breast-cancer stromal cells with TP53 mutations. N Engl J Med. 2008;358:1636. CrossRef
- Roukos DH. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2008;358:197. CrossRef
- Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol. 2008 Aug 23 [Epub ahead of print]. DOI:10.1245/s10434-008-0109-6.
- Predicting and Preventing Positive Surgical Margins and Local Failures in Breast-Conserving Surgery
Annals of Surgical Oncology
Volume 16, Issue 2 , pp 544-545
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors